Circ_nuclear factor I X (circNfix) attenuates pressure overload-induced cardiac hypertrophy via regulating

Jun Pan1, Zhenjun Xu1, Guanjun Guo1

  • 1Department of Thoracic and Cardiovascular Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.

Bioengineered
|September 1, 2021
PubMed

Insights

Circular RNA nuclear factor IX (circNfix) is downregulated in cardiac hypertrophy. Overexpressing circNfix protects against this condition by regulating the microRNA-145-5p/activating transcription factor 3 axis, suggesting it as a potential therapeutic target.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • RNA Biology

Background:

  • Cardiac hypertrophy is a precursor to heart failure, but its progression mechanisms are not fully understood.
  • Circular RNAs (circRNAs) are increasingly recognized for their roles in cardiovascular diseases.
  • The specific function of circ_nuclear factor I X (circNfix) in cardiac hypertrophy remains largely unexplored.

Purpose of the Study:

  • To investigate the role and mechanism of circNfix in the development of cardiac hypertrophy.
  • To explore circNfix as a potential therapeutic target for cardiac hypertrophy.

Main Methods:

  • Cardiac hypertrophy was induced in vitro using angiotensin II (Ang II) on cardiomyocytes.
  • A mouse model of cardiac hypertrophy was established via transverse aortic constriction (TAC) surgery.
  • RNA pull-down, luciferase reporter assays, and fluorescence in situ hybridization (FISH) were employed to elucidate the regulatory mechanism.

Main Results:

  • circNfix expression was significantly downregulated in both Ang II-treated cardiomyocytes and TAC-induced mouse hearts.
  • Overexpression of circNfix ameliorated cardiac hypertrophy in TAC-treated mice.
  • Mechanistically, circNfix was found to bind miR-145-5p, indirectly regulating activating transcription factor 3 (ATF3) expression.

Conclusions:

  • circNfix plays a protective role against cardiac hypertrophy by modulating the miR-145-5p/ATF3 pathway.
  • circNfix represents a promising molecular target for the treatment of cardiac hypertrophy and subsequent heart failure.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
106
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
96
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
581